Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-12 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
21/08/26	SEK 0.8390	+2.44%	1,137,909
20/08/26	SEK 0.8190	-6.93%	4,879,923
19/08/26	SEK 0.8800	-2.22%	1,099,025
18/08/26	SEK 0.9000	-5.06%	1,203,549
17/08/26	SEK 0.9480	-2.77%	800,829

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 16:41:35 21/08/2026 HKT			5-day change	1st Jan Change
0.8390 ^SEK	+2.44%		-13.95%	+1.21%

08-20	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW

Market Cap	166M 17.51M 14.99M 13.99M 12.84M 24.12M 1.68B 24.6M 64.7M 840M 65.76M 64.32M 2.78B	P/E 2026 *	-3.03x	P/E 2027 *	-2.16x
Enterprise Value	150M 15.82M 13.55M 12.64M 11.6M 21.8M 1.51B 22.22M 58.46M 759M 59.42M 58.12M 2.51B	EV / Sales 2026 *	4.78x	EV / Sales 2027 *	-
Free-Float	98.16%	Yield 2026 *	-	Yield 2027 *	-

08-20	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
08-20	Alzinova reports reduced operating loss	FW
08-20	Calendar Thursday, August 20	FW
06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW

08-20	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

08-20	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities	AQ
08-20	Alzinova publishes interim report for the period January - June 2026	AQ
07-07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
06-24	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
06-24	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ

1 day	+2.44%
1 week	-13.95%
Current month	-27.67%
1 month	+27.12%
3 months	+70.70%
6 months	+31.30%
Current year	+1.21%

1 week	0.75	1
1 month	0.63	1.23
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+2.44%	-13.95%	-35.06%	-73.37%	17.51M
LONZA GROUP AG	-0.09%	+3.66%	+2.86%	+24.11%	51.22B
REVOLUTION MEDICINES, INC.	-1.36%	+4.82%	+485.55%	+614.84%	45.38B
BEONE MEDICINES AG	-2.04%	+3.69%	+19.34%	+91.23%	41.97B
IQVIA HOLDINGS INC.	+2.72%	+6.02%	+33.33%	+19.66%	42.15B
CELLTRION, INC.	0.00%	-3.91%	+18.49%	+47.98%	31.95B
ASCENDIS PHARMA A/S	-1.85%	+3.48%	-	-	16.73B
MEDPACE HOLDINGS, INC.	+0.72%	+5.27%	+31.55%	+145.37%	17.1B
EUROFINS SCIENTIFIC SE	-0.74%	+2.61%	+6.29%	+34.45%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.50%	+3.62%	+82.64%	+46.53%	13.91B
Average	+0.03%	+1.09%	+71.67%	+105.64%	27.52B
Weighted average by Cap.	-0.22%	+3.18%	+103.58%	+150.77%

	2026 *	2027 *
Net sales	31.35M 3.31M 2.83M 2.64M 2.42M 4.56M 317M 4.65M 12.22M 159M 12.42M 12.15M 525M	-
Net income	-41M -4.33M -3.7M -3.46M -3.17M -5.96M -414M -6.08M -15.98M -207M -16.24M -15.89M -687M	-77M -8.13M -6.96M -6.49M -5.96M -11.19M -777M -11.41M -30.02M -390M -30.51M -29.84M -1.29B
Net Debt	-16M -1.69M -1.45M -1.35M -1.24M -2.33M -162M -2.37M -6.24M -80.96M -6.34M -6.2M -268M	-19M -2M -1.72M -1.6M -1.47M -2.76M -192M -2.82M -7.41M -96.14M -7.53M -7.36M -318M